{{Expand language | en | page1 =COVAX| time=2021-03-22}}
{{noteTA
|G1=Country
|G2=Korea
|G3=Medicine
}}
[[File:Oxford_AstraZeneca_vaccine_(Indian_version)_2021_C.jpg|200px]]製造的一樽（Covishield）疫苗<ref name="Covax運抵加納">{{cite news |title=Covax捐贈計劃首批物資運抵加納 |url=https://www.bbc.com/zhongwen/trad/world-56193483 |accessdate=2021-03-28 |work=BBC |date=2021-02-25}}</ref>，這款疫苗即為由[[阿斯利康製藥|阿斯利康製藥]]授權生產的[[AZD1222|AZD1222]]疫苗<ref name="印度血清研究所供應COVAX疫苗">{{cite news |title=印度全球最大疫苗生產商 配送COVAX首批疫苗 |url=https://www.rti.org.tw/news/view/id/2092527 |accessdate=2021-03-25 |work=中央廣播電台 |date=2021-02-24 |archive-date=2021-11-22 |archive-url=https://web.archive.org/web/20211122155722/https://www.rti.org.tw/news/view/id/2092527 }}</ref>，是COVAX最主要發送的疫苗，單是印度血清研究所便供應達11億劑<ref name="聯合國新聞疫苗">{{cite news |title=新冠疫苗获取机制公布首份疫苗分配计划 预计今年上半年分发约3.37亿剂疫苗 |url=https://news.un.org/zh/story/2021/02/1077252 |accessdate=2021-03-28 |work=联合国新闻 |date=2021-02-03 |archive-date=2021-02-18 |archive-url=https://web.archive.org/web/20210218104727/https://news.un.org/zh/story/2021/02/1077252 |dead-url=no }}</ref>]]

'''2019冠状病毒病疫苗实施计划'''（{{lang-en|COVID-19 Vaccines Global Access}}，簡稱{{lang|en|COVAX}}）是一项旨在讓全球公平获取[[2019冠状病毒病疫苗|2019冠状病毒病疫苗]]的倡议，該協議由[[联合国儿童基金会|联合国儿童基金会]]（UNICEF）、{{link-en|GAVI}}、[[世界卫生组织|世界卫生组织]]、{{link-en|流行病防备创新联盟|Coalition for Epidemic Preparedness Innovations}}（CEPI）等組織牵头發起。該協議也是[[获取COVID-19工具加速计划|获取COVID-19工具加速计划 (ACT-A)]]的三大支柱之一<ref name="GAVI1">{{Cite web|title=COVAX explained|url=https://www.gavi.org/vaccineswork/covax-explained|accessdate=15 November 2020|work=gavi.org|publisher={{link-en|GAVI}}|archive-date=2021-04-26|archive-url=https://web.archive.org/web/20210426135527/https://www.gavi.org/vaccineswork/covax-explained|dead-url=no}}</ref>。

COVAX原先構想為國際疫苗統籌分配的中樞，代表各國統一資助藥廠開發並購買疫苗，再公平的供應各國疫苗。COVAX之重點在於消弭經濟實力的差距，讓[[開發中國家|中低收入國家]]也能和[[已開發國家|高收入國家]]一樣以同等的速度獲得疫苗，疫苗分配量則僅以國家人口數而定，不因經濟實力有所區別。然而因COVAX資金不足，且高收入國家早已搶先資助藥廠並訂購疫苗，加上疫苗產能嚴重落後，因此COVAX的疫苗取得量低於預期，也使得中低收入國家難以因此受惠。<ref>{{Cite journal|title=A beautiful idea: how COVAX has fallen short|url=https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01367-2/abstract|last=Usher|first=Ann Danaiya|date=2021-06-19|journal=The Lancet|issue=10292|doi=10.1016/S0140-6736(21)01367-2|volume=397|pages=2322–2325|language=en|issn=0140-6736|pmc=PMC8494620|pmid=34147145}}</ref>

截至2021年年初，已有192個國家加盟COVAX，COVAX將向成員國提供20亿剂[[世界卫生组织|世界卫生组织]]認可的疫苗<ref>{{Cite web|title=国际疫苗研究所总干事：需在全球生产160亿剂新冠疫苗|url=https://static.cdsb.com/micropub/Articles/202012/fed3693974834c9e88a3772981f576db.html|author=红星新闻}}</ref>。

== 籌集資金 ==
COVAX主要針對[[發展中國家|發展中國家]]提供至少滿足其最低需求數量的疫苗<ref name=Steinhauser>Gabriele Steinhauser, [https://www.wsj.com/articles/first-free-covid-vaccines-from-who-backed-covax-arrive-in-ghana-11614155319 Ghana Is First Nation to Get Free Covid-19 Vaccines Under Covax Plan] {{Wayback|url=https://www.wsj.com/articles/first-free-covid-vaccines-from-who-backed-covax-arrive-in-ghana-11614155319 |date=20210607065435 }}, ''Wall Street Journal'' (February 24, 2021).</ref>。許多將從COVAX受益的國家，擁有“有限監管能力”（{{lang-en|Limited Regulatory Capacity}}）。共有92個低收入和中等收入國家有資格通過COVAX疫苗「預先市場承諾」（{{lang-en|Advance Market Commitment}}，AMC）融資工具，從而由COVAX機制取得疫苗<ref name=92Eligible>[https://www.gavi.org/news/media-room/92-low-middle-income-economies-eligible-access-covid-19-vaccines-gavi-covax-amc 92 low- and middle-income economies eligible to get access to COVID-19 vaccines through Gavi COVAX AMC] {{Wayback|url=https://www.gavi.org/news/media-room/92-low-middle-income-economies-eligible-access-covid-19-vaccines-gavi-covax-amc |date=20210605183432 }}, Gavi, the Vaccine Alliance (31 July 2020).</ref><ref name=92Eligible/><ref name=Berkley>{{cite web|title=The Gavi COVAX AMC Explained|publisher=Gavi, the Vaccine Alliance|url=https://www.gavi.org/vaccineswork/gavi-covax-amc-explained|author=Seth Berkley|access-date=2021-03-30|archive-date=2021-06-02|archive-url=https://web.archive.org/web/20210602120848/https://www.gavi.org/vaccineswork/gavi-covax-amc-explained|dead-url=no}}</ref>。

2021年2月18日，美國在[[七大工業國組織|七大工業國]]領導人會晤後承諾向COVAX提供40億美元的資金<ref name="G7 financial support COVAX">{{cite news |title=G7 leaders commit US$ 4.3 billion to finance global equitable access to tests, treatments and vaccines in 2021 |url=https://www.who.int/news/item/19-02-2021-g7-leaders-commit-us-4.3-billion-to-finance-global-equitable-access-to-tests-treatments-and-vaccines-in-2021 |accessdate=2021-04-05 |work=WHO |date=2021-02-19 |archive-date=2021-06-04 |archive-url=https://web.archive.org/web/20210604204324/https://www.who.int/news/item/19-02-2021-g7-leaders-commit-us-4.3-billion-to-finance-global-equitable-access-to-tests-treatments-and-vaccines-in-2021 |dead-url=no }}</ref>，其中20億美元即時注入COVAX，其餘20億美元在兩年內發放<ref name="COVAX美國40億美元">{{cite news |title=拜登周五将在G7会议上承诺向COVAX疫苗计划拨款40亿美元 |url=https://cn.reuters.com/article/%E6%8B%9C%E7%99%BB%E5%91%A8%E4%BA%94%E5%B0%86%E5%9C%A8G7%E4%BC%9A%E8%AE%AE%E4%B8%8A%E6%89%BF%E8%AF%BA%E5%90%91COVAX%E7%96%AB%E8%8B%97%E8%AE%A1%E5%88%92%E6%8B%A8%E6%AC%BE40%E4%BA%BF%E7%BE%8E%E5%85%83-idCNL4S2KO4PJ |accessdate=2021-03-30 |work=路透社 |date=2021-02-19}}</ref>，德國亦將為全球疫苗分配機制額外提供15億歐元，歐盟則將給予COVAX的資金增加至10億歐元<ref name="G7疫苗資金">{{cite news |title=G7集團承諾向窮國增接種疫苗援助金至75億歐元 |url=https://news.mingpao.com/ins/%E5%9C%8B%E9%9A%9B/article/20210220/s00005/1613786793359/%E6%96%B0%E5%86%A0%E7%96%AB%E8%8B%97-g7%E9%9B%86%E5%9C%98%E6%89%BF%E8%AB%BE%E5%90%91%E7%AA%AE%E5%9C%8B%E5%A2%9E%E6%8E%A5%E7%A8%AE%E7%96%AB%E8%8B%97%E6%8F%B4%E5%8A%A9%E9%87%91%E8%87%B375%E5%84%84%E6%AD%90%E5%85%83 |accessdate=2021-03-30 |work=明報 |date=2021-02-20 |archive-date=2021-05-21 |archive-url=https://web.archive.org/web/20210521235916/https://news.mingpao.com/ins/%E5%9C%8B%E9%9A%9B/article/20210220/s00005/1613786793359/%E6%96%B0%E5%86%A0%E7%96%AB%E8%8B%97-g7%E9%9B%86%E5%9C%98%E6%89%BF%E8%AB%BE%E5%90%91%E7%AA%AE%E5%9C%8B%E5%A2%9E%E6%8E%A5%E7%A8%AE%E7%96%AB%E8%8B%97%E6%8F%B4%E5%8A%A9%E9%87%91%E8%87%B375%E5%84%84%E6%AD%90%E5%85%83 |dead-url=no }}</ref>。

2021年6月2日，日本首相[[菅義偉|菅義偉]]宣布追加捐助8億美元，連同先前捐贈的2億美元，日本政府捐助金額增至10億美元<ref name="日本捐贈十億美元">{{cite news |title=Japan Can Help！日本對COVAX捐贈十億美元，援台首批124萬劑AZ疫苗下午到 |url=https://www.storm.mg/article/3723967 |work=風傳媒 |date=2021-06-04 |accessdate=2021-06-05 |archive-date=2021-06-05 |archive-url=https://web.archive.org/web/20210605121723/https://www.storm.mg/article/3723967 |dead-url=no }}</ref>。

== 緊急使用清單 ==
[[世界卫生组织|世界卫生组织]]供應的是已列入「緊急使用清單」（{{lang-en|Emergency Use Listing}}，縮寫：EUL）的疫苗<ref name="reuters_Widianto_20210203">{{Cite news| last = Widianto| first = Stanley| title = COVAX to ship enough shots for 3% of poor countries' populations in H1 - WHO| location = [[雅加達|Jakarta]]| work = Reuters| access-date = February 3, 2021| date = January 29, 2021| url = https://www.reuters.com/article/health-coronavirus-indonesia-vaccines-in-idUSKBN29Y19E| archive-date = 2021-04-09| archive-url = https://web.archive.org/web/20210409173053/https://www.reuters.com/article/health-coronavirus-indonesia-vaccines-in-idUSKBN29Y19E| dead-url = no}}</ref>。
=== 2020年 ===
*12月31日，批准將[[德國|德國]][[BioNTech|BioNTech]]與[[美國|美國]][[輝瑞|輝瑞]]合作開發的[[輝瑞－BioNTech_2019冠狀病毒病疫苗|輝瑞–BioNTech疫苗]]（BNT162b2）列入緊急使用清單<ref name="Comirnaty EPAR2">{{cite web|title=Comirnaty EPAR|url=https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty|access-date=23 December 2020|website=European Medicines Agency (EMA)|archive-date=2021-03-17|archive-url=https://web.archive.org/web/20210317131756/https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty|dead-url=no}}</ref><ref>{{cite press release | title=WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access | website=[[World_Health_Organization|World Health Organization]] (WHO) | url=https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access | date=31 December 2020 | access-date=6 January 2021 | archive-date=2021-01-22 | archive-url=https://web.archive.org/web/20210122131246/https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access | dead-url=no }}</ref>。
=== 2021年 ===
*2月16日，批准將[[英國|英國]][[牛津大學|牛津大學]]與[[阿斯利康製藥|阿斯利康製藥]]合作開發，並由[[印度血清研究所|印度血清研究所]]及韓國[[SK集團|SK生物製藥]]代工生產的[[牛津－阿斯特捷利康嚴重特殊傳染性肺炎疫苗|AZ疫苗]]（AZD1222，印度版本：Covishield，韓國版本：Vaxzevria）列入緊急使用清單<ref name="who-2021-02-16">{{cite news |title=WHO authorizes AstraZeneca’s COVID vaccine for emergency use |url=https://apnews.com/article/who-astrazeneca-vaccine-emergency-use-3270b68714c77cf4b292ad25a147323f |accessdate=2021-02-16 |archive-date=2021-06-03 |archive-url=https://web.archive.org/web/20210603045206/https://apnews.com/article/who-astrazeneca-vaccine-emergency-use-3270b68714c77cf4b292ad25a147323f |dead-url=no }}</ref>。
*3月13日，批准將美國[[嬌生公司|嬌生公司]]開發的[[強生2019冠狀病毒病疫苗|嬌生單針接種疫苗]]（Ad26.COV2.S）列入緊急使用清單<ref name="世衛批准強生疫苗">{{cite news |title=世衛批准使用強生新冠疫苗 |url=https://news.now.com/mobile/international/player?newsId=427186 |accessdate=2021-03-30 |work=now新聞 |date=2021-03-13}}</ref>。
*4月30日，批准美國[[莫德纳公司|莫德纳公司]]開發的[[莫德納嚴重特殊傳染性肺炎疫苗|莫德纳疫苗]]（mRNA-1273）列入緊急使用清單<ref name="who-2021-04-30">{{cite news |title=WHO lists Moderna vaccine for emergency use |url=https://www.who.int/news/item/30-04-2021-who-lists-moderna-vaccine-for-emergency-use |accessdate=2021-05-06 |work=World Health Organization |date=2021-04-30 |archive-date=2021-05-06 |archive-url=https://web.archive.org/web/20210506234818/https://www.who.int/news/item/30-04-2021-who-lists-moderna-vaccine-for-emergency-use |dead-url=no }}</ref>。
*5月7日，批准将[[中國國藥集團|中國國藥集團]]開發的[[眾愛可維2019冠狀病毒病疫苗|中國國藥疫苗]]（BBIBP-CorV）列入緊急使用清單<ref>{{cite press release | title=WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations | publisher=[[World_Health_Organization|World Health Organization]] (WHO) | date=7 May 2021 | url=https://www.who.int/news/item/07-05-2021-who-lists-additional-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations | access-date=7 May 2021 | archive-date=2021-05-08 | archive-url=https://web.archive.org/web/20210508031259/https://www.who.int/news/item/07-05-2021-who-lists-additional-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations | dead-url=no }}</ref>。
*6月1日，批准將中國[[科興生物|科興生物]]開發的[[克爾來福2019冠狀病毒病疫苗|中國科興疫苗]]（CoronaVac）列入緊急使用清單<ref>{{Cite web |title=WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations |url=https://www.who.int/news/item/01-06-2021-who-validates-sinovac-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations |access-date=2021-06-02 |work=www.who.int |language=en |archive-date=2021-06-05 |archive-url=https://web.archive.org/web/20210605223719/https://www.who.int/news/item/01-06-2021-who-validates-sinovac-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations |dead-url=no }}</ref>。
*11月3日，批准將由[[印度|印度]]{{link-en|巴拉特生物技術公司|Bharat Biotech}}和{{link-en|印度醫學研究理事會|Indian Council of Medical Research}}合作開發的[[科瓦克辛|科瓦克辛]]（Covaxin）疫苗列入緊急使用清單<ref>{{Cite web | title=WHO issues emergency use listing for eighth COVID-19 vaccine | publisher=[[World_Health_Organization|World Health Organization]] (WHO) | date=3 November 2021 | url=https://www.who.int/news/item/03-11-2021-who-issues-emergency-use-listing-for-eighth-covid-19-vaccine | access-date=3 November 2021 | archive-date=2022-05-05 | archive-url=https://web.archive.org/web/20220505225514/https://www.who.int/news/item/03-11-2021-who-issues-emergency-use-listing-for-eighth-covid-19-vaccine | dead-url=no }}</ref>。
*12月17日，批准將由美國[[諾瓦瓦克斯醫藥|諾瓦瓦克斯醫藥]]（Novavax）及[[印度血清研究所|印度血清研究所]]合作開發的[[諾瓦瓦克斯嚴重特殊傳染性肺炎疫苗|印度版諾瓦瓦克斯疫苗]]（COVOVAX）疫苗列入緊急使用清單<ref>{{Cite web | title=WHO lists 9th COVID-19 vaccine for emergency use with aim to increase access to vaccination in lower-income countries | publisher=[[World_Health_Organization|World Health Organization]] (WHO) | date=17 December 2021 | url=https://www.who.int/news/item/17-12-2021-who-lists-9th-covid-19-vaccine-for-emergency-use-with-aim-to-increase-access-to-vaccination-in-lower-income-countries | access-date=17 December 2021 | archive-date=2021-12-24 | archive-url=https://web.archive.org/web/20211224142249/https://www.who.int/news/item/17-12-2021-who-lists-9th-covid-19-vaccine-for-emergency-use-with-aim-to-increase-access-to-vaccination-in-lower-income-countries | dead-url=no }}</ref>。
*12月21日，批准將由美國[[諾瓦瓦克斯醫藥|諾瓦瓦克斯醫藥]]（Novavax）及{{link-en|流行病預防創新聯盟|Coalition for Epidemic Preparedness Innovations}}（CEPI）合作開發的[[諾瓦瓦克斯嚴重特殊傳染性肺炎疫苗|原廠諾瓦瓦克斯疫苗]]（Nuvaxovid）疫苗列入緊急使用清單<ref>{{Cite web | title=WHO lists 10th COVID-19 vaccine for emergency use : Nuvaxovid | publisher=[[World_Health_Organization|World Health Organization]] (WHO) | date=21 December 2021 | url=https://www.who.int/news/item/21-12-2021-who-lists-10th-covid-19-vaccine-for-emergency-use-nuvaxovid | access-date=21 December 2021 | archive-date=2022-04-03 | archive-url=https://web.archive.org/web/20220403013148/https://www.who.int/news/item/21-12-2021-who-lists-10th-covid-19-vaccine-for-emergency-use-nuvaxovid | dead-url=no }}</ref>。

=== 2022年 ===
*5月19日，批准将由中国[[康希诺生物|康希诺生物]]和[[中国人民解放军军事科学院军事医学研究院|中国人民解放军军事科学院军事医学研究院]]合作开发的[[克威莎2019冠状病毒病疫苗|克威莎疫苗]]（Convidecia）列入紧急使用清单<ref>{{cite news |title=WHO validates 11th vaccine for COVID-19 |url=https://www.who.int/news/item/19-05-2022-who-validates-11th-vaccine-for-covid-19 |accessdate=2022-05-20 |publisher=[[World_Health_Organization|World Health Organization]] (WHO) |date=2022-05-19}}</ref>。

== 疫苗的供應 ==
[[世界衛生組織|世界衛生組織]]在2021年3月指出[[阿斯利康製藥|阿斯利康製藥]]是唯一一家承諾不從這次病毒性肺炎大流行期間牟利的疫苗開發商<ref name="UN-News">{{cite news |title=世卫组织：新冠疫苗的不平等情况“日益变得更加荒谬” |url=https://news.un.org/zh/story/2021/03/1080722 |accessdate=2021-03-24 |work=聯合國新聞 |date=2021-03-22 |archive-date=2021-04-01 |archive-url=https://web.archive.org/web/20210401193705/https://news.un.org/zh/story/2021/03/1080722 |dead-url=no }}</ref>，以成本價供應疫苗<ref name="人民的疫苗">{{cite news |title=人民的疫苗：慈善與牛津 – 阿斯利康疫苗 |url=https://privatebank.jpmorgan.com/gl/zh-hk/insights/giving/the-peoples-vaccine-philanthropy-and-the-oxford-astrazeneca-vaccine |accessdate=2021-03-15 |work=J.P. Morgan |date=2021-01-19 |archive-url=https://web.archive.org/web/20210330044239/https://privatebank.jpmorgan.com/gl/zh-hk/insights/giving/the-peoples-vaccine-philanthropy-and-the-oxford-astrazeneca-vaccine |archive-date=2021-03-30 |dead-url=no }}</ref>，也是唯一一家疫苗研發商同意通過開放技術授權，讓其他疫苗廠家一同參與生產來提升疫苗產量<ref name="世衞稱阿斯利康是榜樣">{{cite news |title=世衞促藥廠授出疫苗專利 冀增加產量 |url=https://www2.hkej.com/landing/mobArticle2/id/2744671/%E4%B8%96%E8%A1%9E%E4%BF%83%E8%97%A5%E5%BB%A0%E6%8E%88%E5%87%BA%E7%96%AB%E8%8B%97%E5%B0%88%E5%88%A9+%E5%86%80%E5%A2%9E%E5%8A%A0%E7%94%A2%E9%87%8F |accessdate=2021-03-25 |work=信報 |date=2021-03-23 |archive-url=https://web.archive.org/web/20210325102313/http://www2.hkej.com/instantnews/current/article/2744671/%E4%B8%96%E8%A1%9E%E4%BF%83%E8%97%A5%E5%BB%A0%E6%8E%88%E5%87%BA%E7%96%AB%E8%8B%97%E5%B0%88%E5%88%A9+%E5%86%80%E5%A2%9E%E5%8A%A0%E7%94%A2%E9%87%8F |archive-date=2021-03-25 |dead-url=no }}</ref>，通過COVAX機制分發的疫苗有90%是阿斯利康製藥授權[[印度血清研究所|印度血清研究所]]<ref name="為貧窮國家尋找疫苗">{{cite news |title=世卫组织为较贫穷国家寻求1000万剂新冠疫苗 |url=https://chinese.aljazeera.net/news/2021/3/27/%E4%B8%96%E5%8D%AB%E7%BB%84%E7%BB%87%E4%B8%BA%E8%BE%83%E8%B4%AB%E7%A9%B7%E5%9B%BD%E5%AE%B6%E5%AF%BB%E6%B1%821000%E4%B8%87%E5%89%82%E6%96%B0%E5%86%A0%E7%96%AB%E8%8B%97 |accessdate=2021-03-28 |work=半島電視台 |date=2021-03-27 |archive-url=https://web.archive.org/web/20210327114916/https://chinese.aljazeera.net/news/2021/3/27/%E4%B8%96%E5%8D%AB%E7%BB%84%E7%BB%87%E4%B8%BA%E8%BE%83%E8%B4%AB%E7%A9%B7%E5%9B%BD%E5%AE%B6%E5%AF%BB%E6%B1%821000%E4%B8%87%E5%89%82%E6%96%B0%E5%86%A0%E7%96%AB%E8%8B%97 |archive-date=2021-03-27 |dead-url=no }}</ref>、韓國[[SK集团|SK生物製藥]]生產的阿斯利康疫苗<ref name="UN-News"/>。

COVAX首輪分配3.372億劑疫苗，印度血清研究所及韓國SK生物製藥分別承擔2.4億劑及9600萬劑阿斯利康疫苗的供應<ref name="COVAX啟動首波配送">{{cite news |title=世衛授權AZ疫苗緊急使用 COVAX啟動首波配送 |url=https://www.cna.com.tw/news/firstnews/202102160014.aspx |accessdate=2021-03-30 |work=中央通訊社 |date=2021-02-19 |archive-date=2021-04-01 |archive-url=https://web.archive.org/web/20210401100652/https://www.cna.com.tw/news/firstnews/202102160014.aspx |dead-url=no }}</ref>，輝瑞製藥也於2021年首季交付120萬劑[[辉瑞－BioNTech_2019冠状病毒病疫苗|輝瑞疫苗]]<ref name="COVAX公布首轮疫苗分配计划">{{cite news |title=COVAX公布首轮疫苗分配计划 |url=https://www.who.int/zh/news/item/02-03-2021-covax-publishes-first-round-of-allocations |accessdate=2021-03-30 |work=世卫组织 |date=2021-03-02 |archive-date=2021-10-21 |archive-url=https://web.archive.org/web/20211021113405/https://www.who.int/zh/news/item/02-03-2021-covax-publishes-first-round-of-allocations }}</ref>。

2021年5月3日，COVAX宣布已經與美國藥廠莫德納达成一项以成本價购买5亿剂[[莫德纳2019冠状病毒病疫苗|莫德纳2019冠状病毒病疫苗]]的协议<ref>{{Cite web|title=Covax signs deal for 500 million Moderna Covid vaccine doses|url=https://themalaysianreserve.com/2021/05/03/covax-signs-deal-for-500-million-moderna-covid-vaccine-doses/|access-date=2021-05-08|date=2021-05-03|work=The Malaysian Reserve|language=en-US|archive-date=2021-05-05|archive-url=https://web.archive.org/web/20210505174146/https://themalaysianreserve.com/2021/05/03/covax-signs-deal-for-500-million-moderna-covid-vaccine-doses/|dead-url=no}}</ref>。

2021年6月2日，日本首相菅義偉宣布向COVAX捐贈3000萬劑AZ疫苗<ref name="日本捐贈十億美元"/>。

2021年6月3日，美国总统拜登宣佈向全球各國捐贈8000万剂2019冠状病毒病疫苗，首批捐贈的2500万剂疫苗中75%通过COVAX发放<ref>{{cite news |title=美国公布首批2500万剂疫苗全球分配计划，75%通过COVAX发放 |url=https://finance.sina.com.cn/tech/2021-06-04/doc-ikqciyzi7610783.shtml |accessdate=2021-06-04 |archive-date=2021-06-04 |archive-url=https://web.archive.org/web/20210604144908/https://finance.sina.com.cn/tech/2021-06-04/doc-ikqciyzi7610783.shtml |dead-url=no }}</ref>。

2021年6月13日，[[七大工業國集團|七大工業國集團]]舉行[[第47屆七大工業國組織會議|第47屆七大工業國組織會議]]期間宣布向COVAX捐贈10億劑疫苗，美國承擔5億劑、英國承擔最少1億劑<ref name="美英各送五亿及一亿剂">{{cite news |title=G7承诺捐十亿疫苗  美英各送五亿及一亿剂 |url=https://www.dw.com/zh/g7%E6%89%BF%E8%AF%BA%E6%8D%90%E5%8D%81%E4%BA%BF%E7%96%AB%E8%8B%97-%E7%BE%8E%E8%8B%B1%E5%90%84%E9%80%81%E4%BA%94%E4%BA%BF%E5%8F%8A%E4%B8%80%E4%BA%BF%E5%89%82/a-57851030 |accessdate=2021-06-20 |work=德國之聲 |date=2021-06-11 |archive-date=2021-06-14 |archive-url=https://web.archive.org/web/20210614052245/https://www.dw.com/zh/g7%E6%89%BF%E8%AF%BA%E6%8D%90%E5%8D%81%E4%BA%BF%E7%96%AB%E8%8B%97-%E7%BE%8E%E8%8B%B1%E5%90%84%E9%80%81%E4%BA%94%E4%BA%BF%E5%8F%8A%E4%B8%80%E4%BA%BF%E5%89%82/a-57851030 |dead-url=no }}</ref>，餘下的4億劑由德國、法國、加拿大及日本捐贈<ref name="G7捐贈全球疫苗承諾">{{cite news |title=盤點G7捐贈全球疫苗承諾！美國5億劑、歐盟7億劑 再次討論病毒起源 |url=https://newtalk.tw/news/view/2021-06-13/588630 |accessdate=2021-06-20 |work=NewTalk新聞 |date=2021-06-13 |archive-date=2021-06-14 |archive-url=https://web.archive.org/web/20210614012946/https://newtalk.tw/news/view/2021-06-13/588630 |dead-url=no }}</ref>。美國總統[[喬·拜登|拜登]]在英格蘭海濱度假勝地[[卡比斯灣|卡比斯灣]]出席七大工業國峰會期間，又和輝瑞執行長博爾拉一同宣布，美國政府向輝瑞購買5億劑美國生產的輝瑞疫苗，用於援助全球中低收入國家，拜登表明美國捐贈疫苗不會附加任何條件<ref name="美捐贈5億劑疫苗給窮國">{{cite news |title=美捐贈5億劑疫苗給窮國 拜登強調「無附加條件」 |url=https://www.cna.com.tw/news/firstnews/202106110010.aspx |accessdate=2021-06-20 |work=自由時報 |date=2021-06-11 |archive-date=2021-06-22 |archive-url=https://web.archive.org/web/20210622053938/https://www.cna.com.tw/news/firstnews/202106110010.aspx |dead-url=no }}</ref>。

2021年7月起，中国国药及科兴生物向COVAX提供疫苗。<ref>{{cite news |title=中国国药和科兴7月起将向COVAX提供疫苗 初期国药6,000万剂、科兴5,000万剂 |url=https://cn.reuters.com/article/gavi-china-pharm-sinovac-vaccine-0712-idCNKBS2EI108 |accessdate=2021-07-12 |archive-date=2021-07-15 |archive-url=https://web.archive.org/web/20210715024219/https://cn.reuters.com/article/gavi-china-pharm-sinovac-vaccine-0712-idCNKBS2EI108 }}</ref>

2022年1月中旬，COVAX已向全球供應10亿剂疫苗。<ref>{{cite news |title=世卫组织：新冠疫苗全球获取机制已交付10亿剂疫苗 |url=https://news.un.org/zh/story/2022/01/1097622 |accessdate=2022-01-17 |archive-date=2022-01-27 |archive-url=https://web.archive.org/web/20220127013633/https://news.un.org/zh/story/2022/01/1097622 }}</ref>

== 分發疫苗 ==
2021年2月24日，60万剂[[阿斯利康疫苗|阿斯利康疫苗]]抵达[[加纳|加纳]]首都[[阿克拉|阿克拉]]，由於加納同意在接收疫苗後儘速配送疫苗及進行接種，因而成為COVAX機制下首個受益國<ref name="Covax運抵加納"/>。[[科特迪瓦|科特迪瓦]]是第二個受益國，印度血清研究所向該國運交了50.4萬劑阿斯利康疫苗<ref name="unnews-2021">{{cite news |title=世卫组织：加纳和科特迪瓦成为非洲首批开展新冠疫苗接种的国家 |url=https://news.un.org/zh/story/2021/03/1079222 |work=联合国新闻 |date=2021-03-01 |access-date=2021-03-30 |archive-date=2022-01-27 |archive-url=https://web.archive.org/web/20220127003352/https://news.un.org/zh/story/2021/03/1079222 }}</ref>。[[北韓|北韓]]也將從印度血清研究所接收170萬劑阿斯利康疫苗<ref name="KBS-kn170">{{cite news |title=新冠疫苗保障机制截至5月将向北韩提供170万剂新冠疫苗 |url=http://world.kbs.co.kr/service/news_view.htm?lang=c&Seq_Code=70832 |accessdate=2021-03-30 |work=KBS |date=2021-03-03 |archive-date=2021-03-22 |archive-url=https://web.archive.org/web/20210322135650/http://world.kbs.co.kr/service/news_view.htm?lang=c&Seq_Code=70832 |dead-url=no }}</ref>。同年4月底，阿斯利康疫苗已在165个以上的国家提供了3亿剂疫苗<ref>{{Cite web|title=AstraZeneca revenues up as it delivers jab to 120 countries via Covax|url=http://www.theguardian.com/business/2021/apr/30/astrazeneca-revenues-up-as-it-delivers-jab-to-120-countries-via-covax-covid|accessdate=2021-04-30|date=2021-04-30|work=the Guardian|language=en|archive-date=2021-05-11|archive-url=https://web.archive.org/web/20210511093152/https://www.theguardian.com/business/2021/apr/30/astrazeneca-revenues-up-as-it-delivers-jab-to-120-countries-via-covax-covid|dead-url=no}}</ref>。[[盧旺達|盧旺達]]於2021年3月3日接收10萬2000劑輝瑞疫苗，是首個通過疫苗獲取機制獲得[[輝瑞疫苗|輝瑞疫苗]]的非洲國家<ref name="un-2021-03-03">{{cite news |title=新冠疫苗获取：苏丹接收80万剂，卢旺达获得34万剂 |url=https://news.un.org/zh/story/2021/03/1079402 |accessdate=2021-05-04 |work=联合国新闻 |date=2021-03-03 |archive-date=2021-05-05 |archive-url=https://web.archive.org/web/20210505220806/https://news.un.org/zh/story/2021/03/1079402 |dead-url=no }}</ref>。

COVAX機制於2021年9月底開始分發透過所購入的科興克爾來福疫苗及國藥眾愛可維疫苗，但遭到非洲及亞洲部分受助國家拒絕接收，南非政府表示中國疫苗所提供的數據不充分，故此拒絕接收世衛分發的中國疫苗，世衛組織亦承認因為有部分國家不願接收中國疫苗，所以這些國家沒有納入這輪分發範圍內<ref name="南非嚇爆急拒絕中國疫苗">{{cite news |title=WHO配送1億劑中國疫苗！南非「嚇爆急拒絕」原因曝光 |url=https://www.ettoday.net/news/20210829/2066927.htm |work=東森新聞 |date=2021-08-29 |accessdate=2021-12-08 |archive-date=2021-12-09 |archive-url=https://web.archive.org/web/20211209203559/https://www.ettoday.net/news/20210829/2066927.htm }}</ref>。

== 參考資料 ==
{{reflist|2}}

== 外部鏈接 ==
*{{En}}[https://www.gavi.org/news/document-library/covax-commitment-agreements  List of participants in the COVAX Facility, Confirmations of intent to participate and AMC-Eligible economies] {{Wayback|url=https://www.gavi.org/news/document-library/covax-commitment-agreements |date=20201018113957 }}
{{Portal bar|國際關係|醫學|病毒|2019冠状病毒病}}
[[Category:世界衛生組織|Category:世界衛生組織]]
[[Category:對2019冠狀病毒病疫情的醫療應對措施|Category:對2019冠狀病毒病疫情的醫療應對措施]]